BC Partners, Bain Consider Offers for Vitamin Firm Nature’s Bounty

  • Some firms may make offers for U.K. unit Holland & Barrett
  • Entire company could fetch a value of as much as $6 billion

Nature’s Bounty Co. may attract bids from a number of private equity firms as owner Carlyle Group LP explores a sale of the vitamin and supplement firm, people familiar with the matter said.

BC Partners and CVC Capital Partners would consider offers for the entire company, the people said, asking not to be identified because the talks are private. Bain Capital and Xio Group are also weighing bids, and some firms may make offers just for Nature’s Bounty’s U.K. unit, Holland & Barrett, they said.

Still, Carlyle would prefer to sell the company whole, one of the people said. The sale process is at an early stage, and no final decisions have been made, they said. The entire company could fetch a value of as much as $6 billion in a sale, people familiar with the plan said last month. 

Carlyle hired advisers to explore either a sale of Nature’s Bounty or Holland & Barrett separately, the people said. Any transaction would add to the $130.7 billion of consumer deals announced globally this year, data compiled by Bloomberg show.

Representatives for Carlyle, BC Partners, CVC, Xio and Bain declined to comment.

Carlyle agreed to buy the Ronkonkoma, New York-based firm, whose brands include “MET-Rx” and “Pure Protein,” in September 2010 in a deal taking the company private valued at about $3.8 billion.

— With assistance by Sarah Syed, and Vinicy Chan

    Before it's here, it's on the Bloomberg Terminal.